Adult Open Studies

Biology

LLUCC-BIOSPECIMEN LABORATORY - SPECIMEN COLLECTION
Loma Linda University Cancer Center Biospecimen Laboratory Specimen Collection Protocol
Mark E. Reeves, MD, PhD

Brain

SWOG-NRG-BN001
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
https://clinicaltrials.gov/ct2/show/NCT02179086
Joseph Kang, MD
Investigator Initiated-AXUMIN
Differentiating glioma recurrence from treatment-induced necrosis using 18F-fluciclovine (anti-18f-facbc) PET and Multiparametric MR Imaging
https://clinicaltrials.gov/ct2/show/NCT03925675
Warren Boling, MD

Breast

Investigator Initiated GRASP-CIPN
A Pilot Study of Intraneural Facilitation for Managing Chemotherapy-Induced Peripheral Neuropathy.
https://clinicaltrials.gov/ct2/show/NCT03272919
Gayathri Nagaraj, MD
SWOG-A011202
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
https://clinicaltrials.gov/ct2/show/NCT01901094
Sharon Lum, MD
SWOG-NRG-BR004
A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors
https://clinicaltrials.gov/ct2/show/NCT04435756
Gayathri Nagaraj, MD

Germ Cell

SWOG-S1823
A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors https://clinicaltrials.gov/ct2/show/NCT04435756
Brian Hu, MD

GI

Colon

SWOG-S0820
Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) with HER-2 Amplification
https://www.clinicaltrials.gov/ct2/show/NCT03365882
Chung-Tsen Hsueh, MD, PhD

Esophagus

Radiation Medicine
A phase II trial of proton-chemotherapy (PCT) for resectable esophageal or esophagogastric junction cancer
https://clinicaltrials.gov/ct2/show/NCT01684904
Gary Yang, MD

Liver

Radiation Medicine
Phase I/II Trial of Stereotactic Body Proton Therapy (SBPT) for Patients with Liver Metastases
https://clinicaltrials.gov/ct2/show/NCT01697371
Gary Yang, MD
NeuWave- NEU-2017-04
A Multicenter Observational Registry to Develop Abation Parameter Guidance for Microwave Liver Ablation of Soft Tissue Lesions
https://clinicaltrials.gov/ct2/show/NCT04107766
Roger Tomihama, MD
NeuWave-NEU-2017-03
A Multicenter Study to Evaluate NEUWAVE Microwave Ablation System Using Ablation Confirmation in Patients with A Soft-Tissue Liver Lesionhttps://clinicaltrials.gov/ct2/show/NCT03753789
Roger Tomihama, MD

Pancreas

Investigator Initiated
A Phase II Trial of Pre-operative Chemotherapy (with Gemcitabine and Nab-paclitaxel) and Stereotactic Body Radiotherapy Followed by Surgery and Chemotherapy in Patients with Resectable Pancreatic https://clinicaltrials.gov/ct2/show/NCT03492671
Naveenraj Solomon, MD

GU

Bladder

UroGen-BL006
A Randomized, Controlled, Open-label Study of the Efficacy, Durability, and Safety of UGN-102 With or Without TURBT in Patients with Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC)
https://clinicaltrials.gov/ct2/show/NCT04688931
Brian Hu, MD

Prostate

COMPPARE NCT03561220
Phase I-II Trial of Hypofractionated Conformal Proton Beam Radiation Therapy for Favorable-risk Prostate Cancer
Jerry Slater, MD

Prostate

Pfizer-C3441021
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Talazoparib with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
https://clinicaltrials.gov/ct2/show/NCT03395197
Chien-Shing Chen, MD, PhD

Urethra

QED-QBGJ398-302
The Proof 302 study of infigratinib in adjuvant urothelial carcinoma is launching soon and patients can be identified NOWhttps://clinicaltrials.gov/ct2/show/NCT04197986
Brian Hu, MD

GYN

Multiple

Investigator Initiated-Paclitaxel
Conventional prophylactic regimen of oral dexamethasone versus short-course intravenous dexamethasone in preventing paclitaxel-related hypersensitivity reactions in gynecologic-oncology patients: A prospective, randomized, open-label study
https://clinicaltrials.gov/ct2/show/NCT03598426
Linda Hong, MD
SWOG-GY019
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
https://clinicaltrials.gov/ct2/show/NCT04095364
Yevgeniya Ioffe, MD

Ovarian

Investigator Initiated HIPEC
Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer
https://clinicaltrials.gov/ct2/show/NCT02672098
Mazdak Momeni, MD
SWOG/NRG-GY009
A Randomized, Phase II/III Study of Pegylated Lipsomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer https://clinicaltrials.gov/ct2/show/NCT02839707
Yevgeniya Ioffe, MD

Cervical

GOG-0263
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
https://clinicaltrials.gov/ct2/show/NCT01101451
Yevgeniya Ioffe, MD

Lung

SWOG-A151216
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
https://clinicaltrials.gov/ct2/show/NCT02194738
Hamid Mirshahidi, MD
SWOG-E4512
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
https://clinicaltrials.gov/ct2/show/NCT02201992
Hamid Mirshahidi, MD
SWOG-LUNGMAP
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
http://clinicaltrials.gov/ct2/show/NCT02154490
Hamid Mirshahidi, MD
SWOG-S1914
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC 
https://clinicaltrials.gov/ct2/show/NCT04214262
Hamid Mirshahidi, MD
SWOG-RTOG-1308
Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC https://clinicaltrials.gov/ct2/show/NCT01993810
David Bush, MD
Calithera-CX-839-014
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy Versus Placebo with Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC) https://clinicaltrials.gov/ct2/show/NCT04265534
Hamid Mirshahidi, MD
SWOG-S1929
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
https://clinicaltrials.gov/ct2/show/NCT04334941
Hamid Mirshahidi, MD
Merck-MK-7339-013-02
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants with Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC)
https://clinicaltrials.gov/ct2/show/NCT04624204
Hamid Mirshahidi, MD
SWOG-A081801
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
https://clinicaltrials.gov/ct2/show/NCT04267848
Hamid Mirshahidi, MD

Lymphoma

SWOG-S1608
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03269669
Muhammad O. Kamal, MD

Melanoma

SWOG-S1801
A Phase II Randomized Study of Adjuvant vs. Neoadjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma (NCT #03698019)
https://clinicaltrials.gov/ct2/show/NCT03698019
Mark E. Reeves, MD, PhD
Castle Biosciences-CBI-2019-SLNBprosp-001
DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes DECIDE
https://clinicaltrials.gov/ct2/show/NCT02355587
Jukes Namm, MD

Multiple

SWOG-S1609
DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors
https://clinicaltrials.gov/ct2/show/NCT02834013
John Wong, MD

Registry

Radiation Medicine
Radiation Medicine Patient Registry
https://clinicaltrials.gov/ct2/show/NCT02436941
Jerry Slater, MD
Penn State-Colon Registry
Prospective observational database of patients with colon cancer at risk of peritoneal recurrence
Maheswari Senthil, MD

Soft Tissue Sarcoma

Radiation Medicine
A phase II study of preoperative proton therapy in soft tissue sarcomas of the extremities and body wall
https://clinicaltrials.gov/ct2/show/NCT01819831
Gary Yang, MD

Solid Tumors

Apollomics-APL-101-01
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03175224
Hamid Mirshahidi, MD
Amgen-20190135-A
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib (proposed generic name for AMG 510) in Combination With Trametinib and in Combination With Trametinib and Panitumumab in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101 Subprotocol A)
https://clinicaltrials.gov/ct2/show/NCT03600883
Hamid Mirshahidi, MD
Amgen-20190135-C
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation 
(CodeBreak 101 Subprotocol C)
https://clinicaltrials.gov/ct2/show/NCT04185883
Hamid Mirshahidi, MD
Amgen-20190135-H
A Phase 1b Study Evaluating the Safety, Tolerability, and Efficacy of AMG 510 (pINN Sotorasib) in Combination with Panitumumab and in Combination with Panitumumab and FOLFIRI in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol H)
https://clinicaltrials.gov/ct2/show/NCT04185883
Hamid Mirshahidi, MD

Transplant

ATARA - ATA129-EBV-302
Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study)
https://clinicaltrials.gov/ct2/show/NCT03394365
Huynh Cao, MD